Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 1Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Patients With Malignant Blood Disease Requiring Hepatitis B Antiviral Medication 1Hepatitis B Reactivation 1

Interventions

Dexamethasone 56Metformin 50Cyclophosphamide 47Saline Solution 39Cytarabine 37Cisplatin 37Zoledronic Acid 34Letrozole 34Sodium Chloride 33Carboplatin 33Bupivacaine 31Bevacizumab 31Docetaxel 30Vincristine 29Methotrexate 29Fluorouracil 28Propofol 27Capecitabine 27Fentanyl 26Doxorubicin 26Rituximab 25Drug Therapy 25Dexmedetomidine 25Prednisone 23Paclitaxel 23Gemcitabine 22Oxaliplatin 21Morphine 21Radiotherapy 19Prednisolone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × tenofovir alafenamide × Clear all
NCT04619082 2024-11-12

TAF to Prevent HBV Reactivation in Cancer Patients

Chiayi Christian Hospital

Phase 4 Active not recruiting
102 enrolled

Hepatitis B Reactivation

NCT06221657 2024-01-24

Clinical Trial for Non-inferiority and Safety of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Patients With Hematologic Malignancies Who Require Prophylactic Hepatitis B Antiviral Treatment

Yonsei University

Phase 4 Not yet recruiting
100 enrolled

Patients With Malignant Blood Disease Requiring Hepatitis B Antiviral Medication

Data powered by HemOnc (CC BY 4.0) Colophon âš¡